Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
Long-Term Safety and Efficacy Data from SIENDO Study in the TP53 Wild-Type Exploratory Subgroup Showed Signals of Improvement in Overall Survival (OS) Regardless of Mismatched Repair Status (MMR) Median OS Not Reached for Selinexor-Treated Patients Who are TP53 Wild-Type pMMR NEWTON, Mass.... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 6, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer
(MedPage Today) -- SEOUL, South Korea -- Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to data from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 5, 2023 Category: Hematology Source Type: news
More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer
(MedPage Today) -- MADRID -- Patients with advanced endometrial cancer had less disease progression and lived longer when they received the immune checkpoint inhibitor (ICI) atezolizumab (Tecentriq) in addition to chemotherapy, a multicenter... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 23, 2023 Category: Hematology Source Type: news
Double Good, Triple Therapy Better in Endometrial Cancer? Double Good, Triple Therapy Better in Endometrial Cancer?
The fast pace of progress in endometrial cancer has taken a step forward with two trials underlining the benefit of immunotherapy plus chemo, while suggesting adding a PARP inhibitor could further boost outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer
(MedPage Today) -- MADRID -- Immunotherapy, chemotherapy, and a PARP inhibitor in the first line improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, according to the DUO-E trial.
The trial assessed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 22, 2023 Category: Hematology Source Type: news
Long-Term Results Show Major Advance in Endometrial Cancer Long-Term Results Show Major Advance in Endometrial Cancer
Maurie Markman, MD, discusses a long-term follow-up trial demonstrating response in patients with endometrial cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 4, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Two Landmark Papers Change Paradigm for Endometrial Cancer Two Landmark Papers Change Paradigm for Endometrial Cancer
Maurie Markman, MD, discusses landmark studies that change the management paradigm for advanced endometrial cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Type 2 Diabetes May Raise Your Risk of Endometrial Cancer
A new study found that women with type 2 diabetes have a higher risk of dying from endometrial cancer. This is important because gynecological cancers can be often be successfully treated, including stage I endometrial cancer, via surgery. (Source: WebMD Health)
Source: WebMD Health - August 17, 2023 Category: Consumer Health News Source Type: news
FDA OKs Dostarlimab Plus Chemo for Endometrial Cancer FDA OKs Dostarlimab Plus Chemo for Endometrial Cancer
The approval moves dostarlimab ' s endometrial cancer indication earlier in the treatment paradigm.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA OKs New Frontline Endometrial Cancer Regimen, First in Decades
(MedPage Today) -- The FDA approved the immune checkpoint inhibitor dostarlimab (Jemperli) plus chemotherapy as a frontline option for certain patients with advanced or recurrent endometrial cancer, the agency announced on Monday.
For adults with... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 31, 2023 Category: American Health Source Type: news
Jemperli (dostarlimab-gxly) Plus Chemotherapy Approved in the US for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Patients with this type of endometrial cancer face significant unmet need and typically experience poor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 31, 2023 Category: Drugs & Pharmacology Source Type: news
FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 31, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves New Frontline Endometrial Cancer Regimen, First in Decades
(MedPage Today) -- The FDA approved the immune checkpoint inhibitor dostarlimab (Jemperli) plus chemotherapy as a frontline option for certain patients with advanced or recurrent endometrial cancer, the agency announced on Monday.
For adults with... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 31, 2023 Category: American Health Source Type: news
Selinexor Increases PFS for Endometrial Cancer With TP53 Mutations
FRIDAY, July 28, 2023 -- Maintenance therapy with selinexor provides durable survival benefits for endometrial cancer with TP53 mutations, according to a study presented during the July 2023 session of the American Society for Clinical Oncology... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 28, 2023 Category: Pharmaceuticals Source Type: news
ASTRO names new board officers, awards fellowships
Members of the American Society for Radiation Oncology (ASTRO) recently electe...Read more on AuntMinnie.comRelated Reading:
ASTRO urges discussion with Congress about staff shortages
ASTRO, ESTRO issue guidelines for lung cancer therapy
ASTRO: Radiation oncology workforce appears stable
ACR, ASTRO cry foul over imaging cuts in 2023 Omnibus bill
ASTRO updates endometrial cancer treatment guideline (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 19, 2023 Category: Radiology Source Type: news
